Context Therapeutics Inc. (CNTX): Price and Financial Metrics

Context Therapeutics Inc. (CNTX): $1.45

0.04 (+2.84%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

D

Add CNTX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#337 of 392

in industry

CNTX Price/Volume Stats

Current price $1.45 52-week high $1.69
Prev. close $1.41 52-week low $0.47
Day low $1.38 Volume 3,616
Day high $1.45 Avg. volume 53,004
50-day MA $1.22 Dividend yield N/A
200-day MA $1.13 Market Cap 23.16M

CNTX Stock Price Chart Interactive Chart >


Context Therapeutics Inc. (CNTX) Company Bio


Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a selective potent antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as ovarian, uterine (endometrial), and breast cancers. The company also engages in developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. In addition, it is involved in the development of Sigma1, a cellular protein that regulates homeostasis, which is in clinical studies for the treatment of breast and prostate cancer. Context Therapeutics Inc. has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of CLDN6xCD3 bsAb. The company was founded in 2015 and is based in Philadelphia, Pennsylvania.


CNTX Latest News Stream


Event/Time News Detail
Loading, please wait...

CNTX Latest Social Stream


Loading social stream, please wait...

View Full CNTX Social Stream

Latest CNTX News From Around the Web

Below are the latest news stories about CONTEXT THERAPEUTICS INC that investors may wish to consider to help them evaluate CNTX as an investment opportunity.

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

CTIM-76 IND filing on track for late Q1 2024 Cash and cash equivalents of $21.7 million as of September 30, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the third quarter ended September 30, 2023, and reported on recent

Yahoo | November 9, 2023

Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76

CTIM-76 exhibits dose-proportional tumor responses and safety in preclinical models Benchmarking studies comparing CTIM-76 with clinical-stage CLDN6 therapies support CTIM-76's differentiated product profile CTIM-76 IND filing on track for late Q1 2024 Data to be presented at SITC 38th Annual Meeting on November 3rd PHILADELPHIA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumor

Yahoo | October 31, 2023

10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis

NEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic ...

Yahoo | October 24, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Pre-market stock movers are worth checking out on Monday as we start off the week with all the latest news this morning!

William White on InvestorPlace | October 2, 2023

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced a poster regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023, at the San Diego Convention Center in San Diego, CA. Details of the presenta

Yahoo | September 27, 2023

Read More 'CNTX' Stories Here

CNTX Price Returns

1-mo 26.09%
3-mo 29.46%
6-mo 28.32%
1-year 135.73%
3-year N/A
5-year N/A
YTD 28.32%
2023 73.39%
2022 -75.50%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!